Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Beijing To Set Up International Pharmaceutical Technology Transfer Platform

This article was originally published in PharmAsia News

Executive Summary

Beijing Equity Exchange, Capital Science & Technology Group and China Center for Pharmaceutical International Exchange recently signed an agreement to jointly establish a platform providing special services for pharmaceutical corporations, R&D institutions and investment organizations. The platform aims to forge a complete pharmaceutical technology transfer service chain for consultation, assessment, investment, acquisition and reorganization. Its competitive advantages include: comprehensive equity exchange system and facilities; worldwide information distribution network; abundant investment resources; international collaboration channels; and capability to integrate medical research institutions. (Click here for more - Chinese Language)

You may also be interested in...



Where The COVID Vaccine Trials Stand: A Snapshot Of The Leaders And Rest Of The Field

With some studies about to finish and others on clinical hold, the coronavirus vaccine field approaches an infection point as the US FDA prepares for its first advisory committee on the topic. Our charts and graphics offer a quick look at what stands where.

Neuromodulation Firm Lands €10.5M For Tinnitus Treatment

Funds will be used to expand European sales of the CE-marked Lenire device, scale-up manufacturing and progress US regulatory and reimbursement plans.

Reckitt Spies Opportunity For Global Supplements Business

RB CEO Laxman Narasimhan sees the potential for the company to establish a global supplements business built on the successes it has enjoyed in the US and China. The comments came as RB reported solid growth in the third quarter, despite struggles for its OTC brands.

UsernamePublicRestriction

Register

GB150348

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel